Orchestra Biomed Holdings Inc
orchestrabiomed.comWhat Do They Do?
Develops therapies for high blood pressure and artery disease with medical-device partners that support clinical development and commercialization.
10-K for FY2025, filed Mar 12, 2026We are a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with…View ↗
Our flagship product candidates are Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) for the treatment of hypertension…View ↗
Our business was formed specifically to pursue a partnership-enabled business model that applies strategies typically used by the…View ↗
Our goal is to accelerate and improve the likelihood of our product innovations reaching patients and providers worldwide by sharing the…View ↗
How Do They Make Money?
Medical-device partners pay upfront for development or rights arrangements; development-related amounts were earned as work progressed. FreeHold sells intracorporeal organ retractors.
10-K for FY2025, filed Mar 12, 2026We recorded the $30.0 million non-refundable, upfront payment received in 2019 from Terumo within deferred revenue and were recognizing the…View ↗
On October 28, 2025, we entered into a termination and right of first refusal agreement (the “Termination and ROFR Agreement”) with Terumo…View ↗
The Company’s revenues are currently comprised of partnership revenues from the Terumo Agreement related to the development and…View ↗
-
10-K for FY2025, filed Mar 12, 2026
FY2025 revenue by product or service ↗
$33.5M
-
10-K for FY2025, filed Mar 12, 2026
$33.5M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Partnership revenue
Recurring
10-K for FY2025, filed Mar 12, 2026 |
98%
FY2022: 81%
|
Partnership revenue, FY2025
$32.9M Sources
|
Recurring |
|
Product revenue
Sold outright
|
1.8%
FY2022: 19%
|
Product revenue, FY2025
$611K Sources
|
Sold outright |
Who Are Their Customers?
Medical-device companies work with Orchestra under collaboration or rights agreements; Medtronic collaborates on AVIM Therapy, and Terumo holds a right of first refusal on Virtue SAB.
10-K for FY2025, filed Mar 12, 2026We are a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with…View ↗
On June 30, 2022, we entered into an exclusive license and collaboration agreement with Medtronic, one of the largest medical device…View ↗
On October 28, 2025, we entered into a termination and right of first refusal agreement (the “Termination and ROFR Agreement”) with Terumo…View ↗
Do Revenues Turn Into Profits?
No. It lost $52.7M in FY2025.
10-K for FY2025, filed Mar 12, 2026
−$51.8MView ↗
10-K for FY2025, filed Mar 12, 2026
−$52.7MView ↗
10-K for FY2025, filed Mar 12, 2026
−$49.5MView ↗
How Are They Changing?
From blank check to product development
The older report describes a blank-check company seeking a healthcare business combination; the latest describes a biomedical developer advancing cardiovascular product candidates through clinical studies and strategic partnerships.
10-K for FY2022, filed Jan 25, 2023 10-K for FY2025, filed Mar 12, 2026Health Sciences Acquisitions Corporation 2 (“we,” “us,” or “our”) is a blank check company incorporated on May 25, 2020 as a Cayman Islands…View ↗
Who Do They Compete With?
Competes with Boston Scientific, Medtronic, Becton Dickinson, Philips, B. Braun, Abbott Laboratories, Cordis, Teleflex, Concept Medical, MicroPort, Eurocor Tech, iVascular, Biosensors International Group, Balton, Invamed, and BIOTRONIK
10-K for FY2025, filed Mar 12, 2026The medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and…View ↗
Loading...
